Annexon To Present New Phase 2 ARCHER Data For ANX007 In Dry AMD Patients With Less Advanced GA At The American Academy Of Ophthalmology 2024 Meeting
Annexon To Present New Phase 2 ARCHER Data For ANX007 In Dry AMD Patients With Less Advanced GA At The American Academy Of Ophthalmology 2024 Meeting
ANX007 Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Photoreceptor Preservation in the Fovea Region Critical for Visual Acuity
ANX007在標準和低光條件下展示了顯著的視力保護，並在對視力敏銳度至關重要的視網膜中心區域保留了顯著的光感受器
Phase 3 Data from Ongoing ARCHER II Pivotal Program Expected Second Half 2026
來自正在進行的ARCHER II關鍵項目的第3階段數據預計在2026年下半年公佈
BRISBANE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced the Company will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting being held October 18-21 in Chicago, Illinois, and at the Eyecelerator conference at AAO being held Thursday, October 17, 2024. ANX007 is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation.
2024年10月15日，加利福尼亞布里斯班（Brisbane）（GLOBE NEWSWIRE）-- Annexon, Inc.（納斯達克：ANNX），一家專注於上游C1q以推進治療身體、大腦和眼睛神經炎症性疾病的生物製藥公司，今天宣佈公司將在正在於2024年10月18日至21日在伊利諾伊州芝加哥舉行的美國眼科醫學學會（AAO）年會和於2024年10月17日星期四在AAO舉辦的Eyecelerator會議上展示來自已完成的ARCHER試驗中關於地理性萎縮（GA）的ANX007新分析。 ANX007是一種首創的非聚乙二醇抗原結合片段（Fab），旨在通過眼內注射劑配方局部阻斷眼睛中的C1q。
譯文內容由第三人軟體翻譯。
